Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
15 août 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza AReported pharmacokinetic (PK) data from the single ascending dose portion of its...
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344
08 août 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc...
Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
14 juil. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
01 juin 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
11 mai 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza AAnnounced a collaboration with the National...
Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
21 avr. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
19 avr. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company...
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
14 avr. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral
12 avr. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal...